Bernitsas Law has advised Lavipharm on raising EUR 51.2 million in equity capital and the December 2022 listing of its new shares on the Athens Exchange.
Lavipharm is an integrated pharmaceutical group engaged in pharmaceutical research, development, production, import, marketing, and distribution in Greece.
"The completion of the share capital increase, especially under the difficult conditions prevailing in the markets, is a significant milestone, as it attests to investors' confidence in the new Lavipharm," Lavipharm Executive Board Member Telemaque Lavidas commented. "At the same time, it contributes towards the more effective and direct implementation of our very carefully designed strategy for placing the group into a growth trajectory."
The Bernitsas Law team included Partner Nikos Papachristopoulos, Senior Associate Sofia Kontou, and Associate Kelly Hatzigaki.